Neil Lee Spector, MD

Associate Professor of Medicine
Sandra Coates Associate Professor
Associate Professor of Pharmacology & Cancer Biology
Member of the Duke Cancer Institute
Campus mail Ste 601, Hock Plaza, Box_2714 Med Ctr, Durham, NC 27710
Phone (919) 684-0409
Email address neil.spector@duke.edu

Education and Training

  • Medical Resident, Medicine, University of Texas at Dallas, 1984 - 1986
  • First Year Neurology Resident, Neurology, University of Texas at Dallas, 1983 - 1984
  • Intern, Medicine, University of Texas at Dallas, 1982 - 1983
  • M.D., University of Medicine and Dentistry of New Jersey, 1982

Publications

Xia, W, Bisi, J, Strum, J, Liu, L, Carrick, K, Graham, KM, Treece, AL, Hardwicke, MA, Dush, M, Liao, Q, Westlund, RE, Zhao, S, Bacus, S, and Spector, NL. "Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers." Cancer Res 66, no. 3 (February 1, 2006): 1640-1647.

PMID
16452223
Full Text

Kelly, H, Graham, M, Humes, E, Dorflinger, LJ, Boggess, KA, O'Neil, BH, Harris, J, Spector, NL, and Dees, EC. "Delivery of a healthy baby after first-trimester maternal exposure to lapatinib." Clinical Breast Cancer 7, no. 4 (2006): 339-341.

Full Text

Bacus, S, Yarden, Y, Xia, W, and Spector, NL. "Rational development of targeted cancer therapies using biomarkers." Laboratory Medicine 37, no. 8 (2006): 482-489.

Full Text

Xia, W, Gerard, CM, Liu, L, Baudson, NM, Ory, TL, and Spector, NL. "Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells." Oncogene 24, no. 41 (September 15, 2005): 6213-6221.

PMID
16091755
Full Text

Burris, HA, Hurwitz, HI, Dees, EC, Dowlati, A, Blackwell, KL, O'Neil, B, Marcom, PK, Ellis, MJ, Overmoyer, B, Jones, SF, Harris, JL, Smith, DA, Koch, KM, Stead, A, Mangum, S, and Spector, NL. "Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23, no. 23 (August 2005): 5305-5313.

PMID
15955900
Full Text

Spector, NL, Xia, W, Burris, H, Hurwitz, H, Dees, EC, Dowlati, A, O'Neil, B, Overmoyer, B, Marcom, PK, Blackwell, KL, Smith, DA, Koch, KM, Stead, A, Mangum, S, Ellis, MJ, Liu, L, Man, AK, Bremer, TM, Harris, J, and Bacus, S. "Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23, no. 11 (April 2005): 2502-2512.

PMID
15684311
Full Text

Bence, AK, Anderson, EB, Halepota, MA, Doukas, MA, DeSimone, PA, Davis, GA, Smith, DA, Koch, KM, Stead, AG, Mangum, S, Bowen, CJ, Spector, NL, Hsieh, S, and Adams, VR. "Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects." Investigational New Drugs 23, no. 1 (January 2005): 39-49.

PMID
15528979
Full Text

Czito, BG, Hong, TJ, Cohen, DP, Tyler, DS, Lee, CG, Anscher, MS, Ludwig, KA, Seigler, HF, Mantyh, C, Morse, MA, Lockhart, AC, Petros, WP, Honeycutt, W, Spector, NL, Ertel, PJ, Mangum, SG, and Hurwitz, HI. "A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon." Int J Radiat Oncol Biol Phys 58, no. 3 (March 1, 2004): 779-785.

PMID
14967434
Full Text

Xia, W, Liu, L-H, Ho, P, and Spector, NL. "Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016." Oncogene 23, no. 3 (January 2004): 646-653.

PMID
14737100
Full Text

Xia, W, Hardy, L, Liu, L, Zhao, S, Goodman, M, Voellmy, R, and Spector, NL. "Concurrent exposure to heat shock and H7 synergizes to trigger breast cancer cell apoptosis while sparing normal cells." Breast Cancer Res Treat 77, no. 3 (February 2003): 233-243.

PMID
12602923
Scholars@Duke

Pages